BCD-248 + daratumumab; Daratumumab + pomalidomide + dexamethasone
Проводит ЗАО «Биокад»
Страница компанииA Phase III Open-Label, Randomized Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab Versus Daratumumab, Pomalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 390 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 10.2032.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–2
- Опухольнужен измеримый очаг (RECIST)
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 26
Критерии включения
- Signed informed consent form.
- Age ≥18 years.
- Documented diagnosis of multiple myeloma according to the IMWG criteria.
- Measurable disease at screening.
- At least 1, but not more than 3 prior lines of antimyeloma therapy, including lenalidomide and a proteasome inhibitor.
- Documented progression according to the IMWG criteria during or after the last line of therapy.
- ECOG score 0-2.
- Resolution of symptoms of toxicity on the prior line of therapy.
Критерии невключения
- Prior therapy with anti-BCMA or anti-CD3 drugs, pomalidomide.
- Refractory to anti-CD38 monoclonal antibodies according to the IMWG criteria.
- Use of any investigational products or medical devices within 28 days prior to randomization or planned use of investigational products or medical devices during participation in this study.
- Hematopoietic stem cell transplantation - prior to randomization or planned during the study
- Plasmapheresis within 14 days prior to randomization.
- Administration of a live attenuated vaccine within 28 days prior to randomization.
- A history of myelodysplastic syndrome or other malignancies other than multiple myeloma within 5 years prior to screening.
- Life-threatening acute complications of the underlying disease.
- Concomitant diseases and/or conditions that significantly increase the risk of AEs during the study:
- Stable angina pectoris, functional class III-IV.
- Unstable angina pectoris and/or myocardial infarction within 6 months prior to randomization.
- Congestive heart failure, NYHA class III-IV.
- Clinically significant (according to the Investigator) cardiac arrhythmia and conduction disorders that do not respond to the maximum possible antiarrhythmic therapy (therapy must be stable for 4 weeks before the planned start of the study therapy).
- Moderate to severe asthma, uncontrolled asthma, asthma with forced expiratory volume in 1 second <50% of predicted normal.
- Chronic obstructive pulmonary disease with forced expiratory volume in 1 second <50% of predicted normal.
- A history of angioneurotic edema, severe respiratory failure.
- Active autoimmune diseases. Patients with type 1 diabetes mellitus and hypothyroidism, requiring only hormone replacement therapy, as well as with skin diseases (vitiligo, alopecia, psoriasis, etc.), which do not require systemic therapy, are allowed to participate.
- Thromboembolic (deep vein thrombosis, pulmonary embolism) or cerebrovascular (stroke, transient ischemic attack) events within 6 months prior to randomization.
- Any infection within 14 days prior to randomization that requires systemic etiological therapy or may, in the Investigator's opinion, increase the risk of infectious complications.
- Any other concomitant disease or condition, which, in the Investigator's opinion, significantly increases the risk of AEs in the study.
- Subjects with amyloidosis, POEMS syndrome, plasma cell leukemia
- CNS involvement or clinical signs of meningeal involvement of multiple myeloma.
- HIV infection, active HBV infection, hepatitis C.
- Hypersensitivity, allergy, or intolerance to monoclonal antibodies or any component of BCD-248, daratumumab, pomalidomide, or dexamethasone.
- Major surgery within less than 14 days prior to the expected start of the study therapy, incomplete recovery from surgery, or planned surgery during participation in the study.
- Pregnancy or breastfeeding, as well as intention to become pregnant or father a child during the study period and within 180 days after receiving the last dose of the IP.
Источник: ClinicalTrials.gov, NCT07742215 · запись обновлена в реестре 3 августа 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 14
- Frequency of MRD negativity by flow cytometry at 12 months from the start of therapy — up to 12 months
- Progression-free survival according to the International Myeloma Working Group (IMWG) criteria — up to 36 months
Цель исследования
The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma. The study will be conducted in a population of male and female subjects aged 18 years and older, with confirmed symptomatic multiple myeloma with measurable disease, who have received one prior line of therapy that included a proteasome inhibitor and lenalidomide and were refractory to lenalidomide, or who have received two or three prior lines of therapy that included a proteasome inhibitor and lenalidomide, with disease progression during or after the last line of therapy.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07742215 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.